Pages that link to "Q47815963"
Jump to navigation
Jump to search
The following pages link to Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial (Q47815963):
Displaying 50 items.
- Targeted Therapies in Triple-Negative Breast Cancer (Q26777736) (← links)
- Triple negative breast cancer: looking for the missing link between biology and treatments (Q26783122) (← links)
- Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Q26786618) (← links)
- The role of taxanes in triple-negative breast cancer: literature review (Q26798356) (← links)
- Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials (Q26822432) (← links)
- Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis (Q26823419) (← links)
- Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline (Q26853619) (← links)
- Current treatment of early breast cancer: adjuvant and neoadjuvant therapy (Q27011658) (← links)
- Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. (Q30249335) (← links)
- Translating neoadjuvant therapy into survival benefits: one size does not fit all. (Q30251738) (← links)
- Strategies for modern biomarker and drug development in oncology (Q30590270) (← links)
- Adjuvant bevacizumab: positive data from a negative trial (Q30660650) (← links)
- An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients (Q31152878) (← links)
- Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. (Q31157714) (← links)
- Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40 (Q33416887) (← links)
- Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer (Q33591690) (← links)
- Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer (Q33628383) (← links)
- Two cases of mastectomy after Paclitaxel + bevacizumab therapy for locally advanced breast cancer (Q33724674) (← links)
- Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways (Q33739807) (← links)
- Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes (Q33874621) (← links)
- Novel therapeutic strategies in the treatment of triple-negative breast cancer (Q33887682) (← links)
- Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. (Q34042709) (← links)
- Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years? (Q34042715) (← links)
- Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis (Q34232366) (← links)
- The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers (Q34258373) (← links)
- Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? (Q34476337) (← links)
- Soy and breast cancer: focus on angiogenesis (Q34477740) (← links)
- Cardiovascular toxicities from systemic breast cancer therapy (Q34630349) (← links)
- Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents (Q34646376) (← links)
- Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy (Q34880943) (← links)
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer (Q34978404) (← links)
- A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer (Q35001280) (← links)
- Triple-negative breast cancer: new perspectives for targeted therapies. (Q35001758) (← links)
- Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours (Q35274974) (← links)
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. (Q35678431) (← links)
- Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean? (Q35782342) (← links)
- Landscape of neoadjuvant therapy for breast cancer (Q35794915) (← links)
- Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy? (Q35815486) (← links)
- Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. (Q35933373) (← links)
- Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. (Q36057458) (← links)
- CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials (Q36069527) (← links)
- Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial (Q36219254) (← links)
- Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases (Q36294948) (← links)
- Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer. (Q36295427) (← links)
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. (Q36306066) (← links)
- Inositol 1, 4, 5-trisphosphate-dependent nuclear calcium signals regulate angiogenesis and cell motility in triple negative breast cancer (Q36334094) (← links)
- Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (Q36379813) (← links)
- Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer (Q36618871) (← links)
- Adjuvant sorafenib for liver cancer: wrong stage, wrong dose (Q36739406) (← links)
- The vasculature: a vessel for bone metastasis. (Q36879125) (← links)